Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C

Figure 1 Basaline features: Psoriasis Area and Severity Index score 11. 5, starting dose of cyclosporine 4 mg/kg per day.

Figure 2 Week 48: Clinical worsening (Psoriasis Area and Severity Index score 22. 8) after reduction cyclosporine therapy.

Figure 3 Treatment with etanercept: At week 12 Psoriasis Area and Severity Index score 16. 2.

Figure 4 Treatment with infliximab: Week 16 Psoriasis Area and Severity Index score 15.

Figure 5 Treatment with adalimumab: Week 12 Psoriasis Area and Severity Index score 22. 4.

Figure 6 Combination therapy with cyclosporine and adalimumab: Week 12 Psoriasis Area and Severity Index score 2. 3.